|
Jul 31
|
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
|
|
Jul 31
|
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates
|
|
Jul 30
|
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
|
|
Jul 3
|
Citizens JMP Maintains Neutral Stance on Intellia Despite Positive Lonvo-z Data
|
|
Jun 27
|
3 Promising Genomics Stocks to Keep an Eye On in 2025
|
|
Jun 25
|
CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?
|
|
Jun 23
|
Intellia Reports Positive 3-Year Lonvo-z Data in HAE Trial at EAACI Congress
|
|
Jun 21
|
Will Intellia Therapeutics (NASDAQ:NTLA) Spend Its Cash Wisely?
|
|
Jun 18
|
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
|
|
Jun 17
|
Verve Therapeutics Skyrockets — Pulling Gene-Editing Stocks Higher — On $1.3 Billion Eli Lilly Takeover
|
|
Jun 17
|
Intellia Therapeutics, Inc. (NTLA) Backed by H.C. Wainwright for 237% Upside Potential
|
|
Jun 15
|
Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress
|
|
Jun 4
|
BEAM Up on FDA's Orphan Drug Status for Gene-Editing Therapy
|
|
Jun 4
|
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
|
|
Jun 4
|
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
|
|
May 29
|
Intellia stock tumbles on safety concerns
|
|
May 29
|
Intellia filing spurs safety concerns over CRISPR drug
|
|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Apr 9
|
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
|
|
Feb 24
|
What's in Store for These 5 Biotech Stocks This Earnings Season?
|